We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest close session, Adma Biologics (ADMA - Free Report) was up +2.01% at $9.13. The stock exceeded the S&P 500, which registered a gain of 0.17% for the day. Meanwhile, the Dow lost 0.18%, and the Nasdaq, a tech-heavy index, added 0.4%.
Prior to today's trading, shares of the infectious disease drug developer had lost 8.3% lagged the Medical sector's gain of 0.65% and the S&P 500's loss of 1.29%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company is expected to report EPS of $0.19, up 18.75% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $139.8 million, up 4.16% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.78 per share and revenue of $536.82 million, which would represent changes of +30% and +5.22%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Adma Biologics holds a Zacks Rank of #3 (Hold).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 11.52. This signifies a discount in comparison to the average Forward P/E of 23.81 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 161, finds itself in the bottom 35% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Adma Biologics (ADMA - Free Report) was up +2.01% at $9.13. The stock exceeded the S&P 500, which registered a gain of 0.17% for the day. Meanwhile, the Dow lost 0.18%, and the Nasdaq, a tech-heavy index, added 0.4%.
Prior to today's trading, shares of the infectious disease drug developer had lost 8.3% lagged the Medical sector's gain of 0.65% and the S&P 500's loss of 1.29%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company is expected to report EPS of $0.19, up 18.75% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $139.8 million, up 4.16% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.78 per share and revenue of $536.82 million, which would represent changes of +30% and +5.22%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Adma Biologics holds a Zacks Rank of #3 (Hold).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 11.52. This signifies a discount in comparison to the average Forward P/E of 23.81 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 161, finds itself in the bottom 35% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.